SCYNEXIS Narrows Losses Amid GSK Dispute, Nasdaq Delisting Threat

TL;DR

**SCYNEXIS is bleeding cash and fighting with GSK, making it a risky bet despite narrowing losses.**

AI Summary

SCYNEXIS INC reported a net loss of $6.885 million for the three months ended June 30, 2025, a significant improvement from the $14.458 million net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $12.276 million, down from $14.047 million in 2024. License agreement revenue increased to $1.364 million in Q2 2025 from $736 thousand in Q2 2024, though it decreased to $1.620 million for the six months ended June 30, 2025, compared to $2.109 million in 2024. Research and development expenses rose slightly to $7.141 million in Q2 2025 from $6.807 million in Q2 2024, but decreased to $12.282 million for the six-month period from $14.019 million in 2024. A key business change is the dispute with GSK regarding the MARIO study, where GSK unilaterally terminated the study despite SCYNEXIS's disagreement, impacting a $30.0 million development milestone. SCYNEXIS reinitiated the MARIO study in May 2025 and billed GSK a $10.0 million milestone. The company faces liquidity risks, with an accumulated deficit of $388.8 million and cash and investments totaling $46.5 million as of June 30, 2025. Additionally, SCYNEXIS received a Nasdaq minimum bid price notification on June 20, 2025, as its stock traded below $1.00 per share.

Why It Matters

This filing reveals SCYNEXIS's precarious financial position and a critical dispute with GSK over the MARIO study, which could significantly impact future revenue and development milestones. For investors, the ongoing disagreement with GSK and the Nasdaq minimum bid price notification create substantial uncertainty regarding the company's ability to fund operations and maintain its listing. Employees face potential instability if the company cannot secure additional capital or resolve its financial challenges. Customers and the broader market, particularly those relying on novel antifungal treatments, could see delays or cessation of development for critical drugs like ibrexafungerp and SCY-247, especially given the WHO's highlighted unmet need in this area. The competitive landscape for antifungal solutions remains intense, and SCYNEXIS's struggles could open doors for rivals.

Risk Assessment

Risk Level: high — SCYNEXIS reported an accumulated deficit of $388.8 million as of June 30, 2025, and a net decrease in cash, cash equivalents, and restricted cash of $5.331 million for the six months ended June 30, 2025. The company also received a Nasdaq minimum bid price notification on June 20, 2025, indicating its stock traded below $1.00 per share, posing a delisting risk if compliance is not regained by December 17, 2025.

Analyst Insight

Investors should exercise extreme caution and consider divesting, given the high liquidity risk, the significant dispute with GSK over a $30.0 million milestone, and the Nasdaq delisting threat. Monitor the outcome of the GSK dispute and the company's ability to regain Nasdaq compliance before considering any new positions.

Financial Highlights

debt To Equity

N/A

revenue

$1.364M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$6.885M

eps

N/A

gross Margin

N/A

cash Position

$46.5M

revenue Growth

+85.3%

Revenue Breakdown

Key Numbers

• $6.885M — Net Loss (Q2 2025) (Reduced from $14.458M in Q2 2024)
• $12.276M — Net Loss (Six Months 2025) (Reduced from $14.047M in Six Months 2024)
• $388.8M — Accumulated Deficit (As of June 30, 2025, indicating significant historical losses)
• $46.5M — Cash & Investments (As of June 30, 2025, representing capital resources)
• $10.0M — GSK Milestone Billed (Billed in Q2 2025 despite GSK's purported termination)
• $30.0M — Disputed GSK Milestone (Tied to MARIO study resumption and continuation, currently in dispute)
• $1.00 — Nasdaq Minimum Bid Price (Company stock fell below this threshold, triggering a delisting warning)
• 41,924,941 — Common Stock Outstanding (As of August 8, 2025)
• 180 — Days to Regain Nasdaq Compliance (From June 20, 2025, until December 17, 2025)
• 1,639 — Stock-based compensation expense (in thousands) (For the six months ended June 30, 2025, up from 1,464 in 2024)

Key Players & Entities

• SCYNEXIS, Inc. (company) — biotechnology company developing antifungal compounds
• GlaxoSmithKline Intellectual Property (No. 3) Limited (company) — licensee of ibrexafungerp rights
• FDA (regulator) — U.S. Food and Drug Administration, lifted clinical hold on ibrexafungerp
• Nasdaq Global Market (regulator) — exchange where SCYNEXIS common stock is listed, issued minimum bid price notification
• WHO (regulator) — World Health Organization, highlighted unmet need in fungal infections
• $388.8 million (dollar_amount) — accumulated deficit as of June 30, 2025
• $46.5 million (dollar_amount) — cash and cash equivalents and investments as of June 30, 2025
• $10.0 million (dollar_amount) — development milestone billed to GSK in Q2 2025
• $30.0 million (dollar_amount) — development milestone tied to MARIO study resumption and continuation
• $1.364 million (dollar_amount) — license agreement revenue for Q2 2025

FAQ

Risk Factors

• Dispute with GSK over MARIO Study [high — legal]: GSK unilaterally terminated the MARIO study, impacting a $30.0 million development milestone. SCYNEXIS has disputed this termination and reinitiated the study, billing GSK a $10.0 million milestone, creating significant legal and financial uncertainty.
• Liquidity and Going Concern [high — financial]: As of June 30, 2025, SCYNEXIS has an accumulated deficit of $388.8 million and only $46.5 million in cash and investments, raising substantial doubt about its ability to continue as a going concern.
• Nasdaq Minimum Bid Price Compliance [high — regulatory]: The company received a Nasdaq minimum bid price notification on June 20, 2025, as its stock traded below $1.00. SCYNEXIS has 180 days, until December 17, 2025, to regain compliance, or it faces delisting.
• Dependence on Key Partnerships [medium — operational]: The dispute with GSK highlights the company's reliance on major partners for development milestones. The termination of the MARIO study by GSK demonstrates the risk associated with such dependencies.
• Net Loss and Burn Rate [medium — financial]: Despite a reduction in net loss to $6.885 million in Q2 2025 from $14.458 million in Q2 2024, the company continues to incur significant operating losses, consuming its cash reserves.
• Research and Development Expenses [medium — operational]: R&D expenses increased slightly in Q2 2025 to $7.141 million from $6.807 million in Q2 2024, indicating ongoing investment in product development, which contributes to cash burn.

Industry Context

SCYNEXIS operates in the highly competitive biotechnology sector, focusing on novel anti-infective therapies. The industry is characterized by long development cycles, significant R&D investment, and reliance on strategic partnerships for funding and market access. Companies like SCYNEXIS face intense pressure to demonstrate clinical efficacy and navigate complex regulatory pathways.

Regulatory Implications

The Nasdaq minimum bid price notification presents an immediate regulatory risk, threatening delisting and impacting investor confidence. Failure to regain compliance by December 17, 2025, could severely limit the company's access to capital markets and liquidity.

What Investors Should Do

1. Monitor GSK Dispute Resolution
2. Track Nasdaq Compliance Efforts
3. Assess Cash Burn and Runway
4. Evaluate Clinical Development Progress

Key Dates

• 2025-06-30: End of Q2 2025 — Reported net loss of $6.885 million and cash/investments of $46.5 million. Accumulated deficit reached $388.8 million.
• 2025-06-20: Nasdaq Minimum Bid Price Notification — Stock fell below $1.00, triggering a 180-day compliance period ending December 17, 2025, posing a delisting risk.
• 2025-05-01: SCYNEXIS Reinitiated MARIO Study — Company took action to resume the study after GSK's purported termination, billing a $10.0 million milestone and escalating the dispute.
• 2024-06-30: End of Q2 2024 — Reported net loss of $14.458 million, providing a comparison point for the improved Q2 2025 results.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates SCYNEXIS's history of unprofitability, with a significant deficit of $388.8 million as of June 30, 2025.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period. (SCYNEXIS reported net losses of $6.885 million for Q2 2025 and $12.276 million for the first six months of 2025, showing a trend of reduced losses.)

Development Milestone

A specific achievement or target in the development process of a product, often triggering a payment from a partner or licensee. (The dispute with GSK centers around a $30.0 million development milestone related to the MARIO study, highlighting the financial impact of partnership disagreements.)

Nasdaq Minimum Bid Price

A rule set by the Nasdaq stock exchange requiring listed companies to maintain a minimum stock price (typically $1.00) to remain listed. (SCYNEXIS received a non-compliance notice, indicating a significant risk of delisting if the stock price does not recover.)

Going Concern

The assumption that a company will continue to operate for the foreseeable future, typically at least 12 months. (The company's financial position, including its accumulated deficit and cash reserves, raises substantial doubt about its ability to continue as a going concern.)

Year-Over-Year Comparison

SCYNEXIS INC has shown an improvement in its net loss for the three months ended June 30, 2025, reducing it to $6.885 million from $14.458 million in the prior year's quarter. While license agreement revenue saw a significant increase in Q2 2025, it declined year-to-date. Research and development expenses have been managed, decreasing for the six-month period. However, new risks have emerged, notably the dispute with GSK and the Nasdaq delisting warning, which were not present in the prior period's filings.

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 per share SCYX Nasdaq Global Market

Filing Documents

• scyx-20250630.htm (10-Q) — 1880KB
• scyx-ex31_1.htm (EX-31.1) — 18KB
• scyx-ex31_2.htm (EX-31.2) — 18KB
• scyx-ex32_1.htm (EX-32.1) — 12KB
• 0000950170-25-107985.txt ( ) — 8820KB
• scyx-20250630.xsd (EX-101.SCH) — 1048KB
• scyx-20250630_htm.xml (XML) — 2061KB

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION 1 Item 1.

Financial Statements

Financial Statements 1 Unaudited Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 1 Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 2 Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 3 Notes to the Condensed Consolidated Financial Statements (unaudited) 4 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 23 Item 4.

Controls and Procedures

Controls and Procedures 23

OTHER INFORMATION

PART II OTHER INFORMATION 23 Item 1.

Legal Proceedings

Legal Proceedings 23 Item 1A.

Risk Factors

Risk Factors 23 Item 6. Exhibits 25

Signatures

Signatures 26 Table of Contents

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

Financ ial Statements

Item 1. Financ ial Statements. SCYNEXIS, INC. UNAUDITED CONDENS ED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 11,020 $ 16,051 Short-term investments 33,765 43,249 Prepaid expenses and other current assets 1,578 2,184 License agreement receivable 10,000 753 License agreement contract asset — 9,509 Restricted cash 135 435 Total current assets 56,498 72,181 Investments 1,736 15,846 Deferred offering costs 417 417 Restricted cash 109 109 Operating lease right-of-use asset 1,934 2,090 Total assets $ 60,694 $ 90,643 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 6,172 $ 4,569 Accrued expenses 2,477 3,793 Deferred revenue, current portion 1,770 1,642 Operating lease liability, current portion 444 407 Convertible debt — 13,688 Total current liabilities 10,863 24,099 Deferred revenue 515 1,294 Warrant liability 2,904 7,998 Operating lease liability 1,945 2,175 Total liabilities 16,227 35,566 Commitments and contingencies Stockholders' equity: Preferred stock, $ 0.001 par value, authorized 5,000,000 shares as of June 30, 2025 and December 31, 2024; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value, 150,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 39,174,941 and 37,973,991 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 42 41 Additional paid-in capital 433,236 431,571 Accumulated deficit ( 388,811 ) ( 376,535 ) Total stockholders' equity 44,467 55,077 Total liabilities and stockholders' equity $ 60,694 $ 90,643 The accompanying notes are an integral part of the financial statements. 1 Table of Contents

Legal Proceedings

Legal Proceedings On November 7, 2023, a securities class action was filed by Brian Feldman against the Company and certain of the Company's executives in the United States District Court, District of New Jersey, alleging that, during the period from March 31, 2023 to September 22, 2023, the Company made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects, alleging specifically that the Company failed to disclose to investors: (1) that the equipment used to manufacture ibrexafungerp was also used to manufacture a non-antibacterial beta-lactam drug substance, presenting a risk of cross-contamination; (2) that the Company did not have effective internal controls and procedures, as well as adequate internal oversight policies to ensure that its vendor complied with current Good Manufacturing Practices ("cGMP"); (3) that, due to the substantial risk of cross-contamination, the Company were reasonably likely to recall its ibrexafungerp tablets and halt its clinical studies; and (4) as a result of the foregoing, the Company's statements about its business, operations, and prospects were materially misleading and/or lacked a reasonable basis. The complaint seeks unspecified damages, interest, fees and costs on behalf of all persons and entities who purchased and/or acquired shares of the Company's common stock between March 31, 2023 to September 22, 2023. The court granted the Company's motion to dismiss with leave to amend on July 30, 2025. On May 1, 2024, and again on June 4, 2024, purported shareholder derivative complaints were filed in the United States District Court, District of New Jersey. The complaints name the Company's directors and certain of its officers and assert state and federal claims based on the same alleged misstatements as the securities class action complaint. These cases seek unspecified damages, disgorgement, unspecified equitable relief, in

View Full Filing

View this 10-Q filing on SEC EDGAR